Marinus Pharmaceuticals (MRNS) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free MRNS Stock Alerts $1.33 -0.01 (-0.75%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:34 AM | americanbankingnews.comFY2027 EPS Estimates for Marinus Pharmaceuticals, Inc. Cut by HC Wainwright (NASDAQ:MRNS)May 13 at 2:16 AM | americanbankingnews.comResearch Analysts Set Expectations for Marinus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MRNS)May 12, 2024 | americanbankingnews.comFY2027 EPS Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Lifted by Leerink PartnrsMay 11, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost ManagementMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)May 9, 2024 | americanbankingnews.comHC Wainwright Weighs in on Marinus Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:MRNS)May 9, 2024 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) PT Lowered to $11.00May 8, 2024 | washingtonpost.comMarinus Pharmaceuticals: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug TrialsMay 8, 2024 | msn.comMarinus Pharmaceuticals GAAP EPS of -$0.68 misses by $0.02, revenue of $7.68M misses by $1.48MMay 8, 2024 | msn.comMarinus Pharmaceuticals CEO to Speak at RBC Healthcare ConferenceMay 8, 2024 | finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Price Target Lowered to $11.00 at HC WainwrightHC Wainwright reduced their target price on shares of Marinus Pharmaceuticals from $27.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday.May 2, 2024 | marketbeat.comMarinus Pharmaceuticals (MRNS) Set to Announce Quarterly Earnings on WednesdayMarinus Pharmaceuticals (NASDAQ:MRNS) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | businesswire.comMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceMay 1, 2024 | finance.yahoo.comMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024April 28, 2024 | marketbeat.comabrdn plc Acquires New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)abrdn plc acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 552,572 shares of the biopharmaceutical company's stock, valued at approximately $6,006,000. abrdn plcApril 24, 2024 | investing.comMarinus Pharmaceuticals Inc (MRNS)April 18, 2024 | marketbeat.comTruist Financial Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $10.00Truist Financial reduced their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday.April 18, 2024 | marketbeat.comCantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now forecasts that theApril 17, 2024 | msn.comBaird Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | msn.comRBC Capital Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Neutral" at Robert W. BairdRobert W. Baird cut Marinus Pharmaceuticals from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $20.00 to $2.00 in a research report on Tuesday.April 15, 2024 | markets.businessinsider.comMaintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial HealthApril 15, 2024 | bizjournals.comMarinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidateApril 15, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Sector Perform" at Royal Bank of CanadaRoyal Bank of Canada downgraded Marinus Pharmaceuticals from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $24.00 to $3.00 in a report on Monday.April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | markets.businessinsider.comMarinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionApril 15, 2024 | msn.comWhy Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?April 15, 2024 | investorplace.comWhy Are Stocks Up Today?April 15, 2024 | investorplace.comWhy Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?April 15, 2024 | marketwatch.comMarinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping CriteriaApril 15, 2024 | businesswire.comMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsApril 15, 2024 | marketbeat.comTrading was temporarily halted for "MRNS" at 06:04 AM with a stated reason of "News pending."April 10, 2024 | marketbeat.comMarinus Pharmaceuticals' (MRNS) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday.April 9, 2024 | msn.comMarinus Pharmaceuticals Awards Stock Options to New Employees as InducementApril 8, 2024 | marketbeat.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of "Moderate Buy" by BrokeragesMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have givenApril 5, 2024 | morningstar.comMarinus Pharmaceuticals Inc MRNSApril 5, 2024 | businesswire.comMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 3, 2024 | marketbeat.comAssenagon Asset Management S.A. Reduces Stock Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)Assenagon Asset Management S.A. lessened its stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) by 47.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 271,157 shares of the biMarch 27, 2024 | finance.yahoo.comMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant ReviewMarch 27, 2024 | businesswire.comMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant ReviewMarch 27, 2024 | marketbeat.comLeerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2025 EPS estimates for Marinus Pharmaceuticals in a note issued to investors on Sunday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical companyMarch 26, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)HC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday.March 20, 2024 | finance.yahoo.comDo Options Traders Know Something About Marinus (MRNS) Stock We Don't?March 15, 2024 | ca.finance.yahoo.comMRNS Jul 2024 16.000 callMarch 15, 2024 | ca.finance.yahoo.comMRNS Mar 2024 7.000 putMarch 12, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Shares Up 8.5%Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Up 8.5% Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. MRNS Media Mentions By Week MRNS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.040.55▲Average Medical News Sentiment MRNS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼223▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BioXcel Therapeutics News Today Vaccitech News Today Barinthus Biotherapeutics News Today Connect Biopharma News Today Chimerix News Today Spero Therapeutics News Today Oncolytics Biotech News Today Corvus Pharmaceuticals News Today Jaguar Health News Today Hookipa Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
